The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b/2 study of TP-0903 and decitabine targeting mutant TP53 and/or complex karyotype in patients with untreated acute myeloid leukemia ≥ age 60 years: Phase 1b interim results.
 
Alice S. Mims
Consulting or Advisory Role - Abbvie/Genentech; Agios; Astellas Pharma; Jazz Pharmaceuticals; Jazz Pharmaceuticals; PTC Therapeutics
 
Ying Huang
No Relationships to Disclose
 
Eric Eisenmann
No Relationships to Disclose
 
Daelynn Buelow
No Relationships to Disclose
 
Ronan T. Swords
No Relationships to Disclose
 
Matthew Charles Foster
No Relationships to Disclose
 
Tara L. Lin
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma (Inst); Bio-Path Holdings, Inc (Inst); Celgene (Inst); Celyad (Inst); CicloMed (Inst); Cleave Biosciences (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); incyte (Inst); Novartis (Inst); Pfizer (Inst); Prescient Therapeutics (Inst); Seagen (Inst); Tolero Pharmaceuticals (Inst); Trovagene (Inst)
 
Maria R. Baer
Research Funding - Abbvie (Inst); Ascentage Pharma (Inst); FORMA Therapeutics (Inst); Kite, a Gilead company (Inst); Kura Oncology (Inst); Takeda (Inst)
 
Tibor Kovacsovics
Consulting or Advisory Role - Agios; Novartis; Stemline Therapeutics; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Cantex (Inst); Gilead Sciences (Inst); Glycomimetics (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Syndax (Inst)
 
Zeina Al-Mansour
No Relationships to Disclose
 
Mona Stefanos
No Relationships to Disclose
 
Franchesca Druggan
No Relationships to Disclose
 
Timothy Chen
No Relationships to Disclose
 
Ashley Yocum
No Relationships to Disclose
 
Uma Borate
Honoraria - RUNX1 Research Program
Consulting or Advisory Role - Abbvie; Agios; Astellas Pharma; Blueprint Medicines; Genentech; Novartis
Research Funding - Abbvie; Incyte; Jazz Pharmaceuticals; Novartis; Pfizer
Travel, Accommodations, Expenses - Novartis
 
Brian J. Druker
Leadership - Amgen; Burroughs Wellcome Fund; Vincerx Pharma
Stock and Other Ownership Interests - Amgen; Blueprint Medicines; Blueprint Medicines; Enliven Therapeutics; GRAIL; MolecularMD; Recludix Pharma; Vincerx Pharma
Honoraria - Aptose Biosciences; Cepheid
Consulting or Advisory Role - Adela; Aileron Therapeutics; Aptose Biosciences; Blueprint Medicines; Celgene; Cepheid; Enliven Therapeutics; Gilead Sciences; GRAIL; Iterion Therapeutics; MolecularMD; Nemucore Medical Innovations; Novartis; Patient True Talk; Recludix Pharma; RUNX1 Research Program; RUNX1 Research Program; Therapy Architects; Third Coast Therapeutics; VBL Therapeutics; Vincerx Pharma; Vivid Biosciences
Research Funding - AstraZeneca (Inst); Enliven Therapeutics (Inst); Novartis (Inst); Recludix Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Dana Farber Inventions #2063 and #2524; OHSU Invention #0843 - Issue payment from Sun Pharma in 2021; Patent #4326534; Detection of gleevec resistant mutations; US Patent # 10473667, Methods Apparatuses and Sustems for Detecting and Quantifying Phosphoproteins; US Patent # 11049247, Methods, Systems, and Apparatuses for Quantitative Analysis of Heterogeneous Biomarker Distribution; US Patent # 7592142, Detection of gleevec resistance; US Patent #10664967, Methods, Systems, and Apparatuses for Quantitative Analysis of Heterogeneous Biomarker Distribution; US Patent #6958335, Treatment of gastrointestinal stromal tumors; US Patent #7416873, Detection of gleevec resistant mutations
Travel, Accommodations, Expenses - Amgen; Amgen
(OPTIONAL) Uncompensated Relationships - Beat AML; Burroughs Wellcome Fund; CureOne
 
Amy Burd
No Relationships to Disclose
 
Ross L. Levine
Leadership - Qiagen
Stock and Other Ownership Interests - Ajax; Anovia; Auron Therapeutics; BAKX Therapeutics; C4 Therapeutics; Epiphanes; Imago Pharma; IsoPlexis; Kurome Therapeutics; Loxo; Mana Therapeutics; Mission Bio; Prelude Therapeutics; Qiagen; Scorpion Therapeutics; Syndax; Zentalis
Honoraria - Amgen; Celgene; Genome Canada; Gilead Sciences; Incyte; Janssen; Lilly; The Mark Foundation For Cancer Research
Consulting or Advisory Role - BMS; Bridge Medicines; Bridge Therapeutics; Bridgebio; C4 Therapeutics; Celgene; Daiichi; Imago Pharma; IsoPlexis; Jubilant Biosys; Loxo; MorphoSys; Novartis; Prelude Therapeutics; Roche; Stelexis Therapeutics; Vida Ventures
Speakers' Bureau - Amgen; Lilly
Research Funding - Celgene; Cure Breast Cancer Foundation; ECOG-ACRIN; Prelude Therapeutics; Roche; The Mark Foundation For Cancer Research
Travel, Accommodations, Expenses - Auron Therapeutics; C4 Therapeutics; Constellation Pharmaceuticals; Genome Canada; Incyte; Qiagen
 
Sharyn D. Baker
No Relationships to Disclose
 
John C. Byrd
Stock and Other Ownership Interests - Vincerx Pharma
Honoraria - AstraZeneca; Novartis; Novartis; Syndax; Trillium Therapeutics
Consulting or Advisory Role - AstraZeneca; Janssen; Kura Oncology; Novartis; Syndax
Research Funding - Acerta Pharma (Inst); Pharmacyclics (Inst); Zencor
Patents, Royalties, Other Intellectual Property - OSU Patents (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Janssen; Novartis; Pharmacyclics; TG Therapeutics